Agentase LLC (an ICx Company acquired by FLIR Systems)
Agentase, LLC (an ICx company) is a technology company founded in December 1998 by Dr. Keith LeJeune and Dr. Alan Russell, two of the nation's leading experts on enzyme-polymer hybrid materials. The company possesses proprietary and patented technology in the synthesis and potential applications of enzyme containing polymers. ICx Technologies agrees to be acquired by FLIR Systems 8/16/10
www.agentase.com
|
ALung Technologies, Inc.
ALung has developed the Hemolung™, an extracorporeal artificial lung that will replace or supplement the ventilator in the ICU for acute respiratory failure. The Hemolung will provide 50% of a patient’s respiratory need, allowing the lungs to heal, eliminating the need for intubation, sedation and mechanical ventilation. The Hemolung™ will reduce the incidence of ventilator associated pneumonia and hospital length of stay, resulting in a reduced cost of care for these patients. The Company has completed animal and human trials and expects initiate commercialization in Europe in Q1 2013.
www.alung.com
|
Blue Belt Technologies, Inc.
Blue Belt Technologies, Inc., a Carnegie Mellon University spin-off company, was formed in 2003 to commercialize novel device solutions for medical interventions. Blue Belt draws from the extensive experience of its research team to develop devices in computer-assisted surgery and diagnosis. The company has developed Precision Freehand Sculpting™ (PFS), a solution that reintroduces robotics into the operating room to enable safer, faster, and more accurate treatment of osteoarthritis and other bone related conditions. PFS will address the challenges of Minimally Invasive Surgery, with the goal of improving patient outcomes and lowering healthcare costs.
www.bluebelttech.com
|
Carmell Therapeutics Corporation
Carmell has developed a method of manufacturing biologically-active plastic materials from blood plasma. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell is focused on products for the sports medicine market with devices for the repair of tendon and cartilage injuries.
www.carmellrx.com
|
Cellumen, Inc. (Acquired by Apredica/Cyprotex)
Cellumen is the Systems Cell Biology company that is focused on delivering cellular models of disease and cytotoxicity that will revolutionize the drug discovery process and improve the quality of compounds entering clinical trials. The same systems cell biology approach is also being developed to optimize personalized medicine for clinical trials. Cellumen was acquired by Apredica/Cyprotex 8/4/10.
www.cellumen.com
|